Hindman Andrew A. 4
4 · Theravance Biopharma, Inc. · Filed Jul 3, 2019
Insider Transaction Report
Form 4
Hindman Andrew A.
SVP, Chief Financial Officer
Transactions
- Award
Ordinary Shares
2019-07-01+50,000→ 50,000 total - Award
Share Option (Right to Buy)
2019-07-01+260,000→ 260,000 totalExercise: $16.94Exp: 2029-06-30→ Ordinary Shares (260,000 underlying)
Footnotes (1)
- [F1]This option may be exercised with respect to the first 25% of the shares subject to this option when optionee completes 12 months of continuous service after the Grant Date. This option may be exercised with respect to an additional 1/48th of the shares subject to this option when optionee completes each month of continuous service thereafter. The option shall be fully vested and exercisable on the 4-year anniversary of the Grant Date provided optionee has remained in continuous service through such date.